Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

MIRABEGRON

All products: Limited Use (codes 290)

Other products in the same Health Canada class (G04BD) — coverage varies; not interchangeable

  • Fesoterodine (Toviaz): limited Use 290
  • Propiverine (Mictoryl Pediatric): limited Use 530

Myrbetriq · DIN 02402882 · 50mg · extended release tablet

Limited Use — Reason for Use code 290 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 290 required
Write on scriptLU code 290 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 290
Reason for Use code 290 For patients with urinary frequency, urgency or urge incontinence who have: Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects. NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed. Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden. Coverage limit: LU Authorization Period: Indefinite
Savings card: innoviCares lists Myrbetriq (Ontario list dated 2026-09-10) — pays part of the brand-versus-generic difference after other coverage; free sign-up. (innovicares.ca ↗)
1 brand, same coverage
Myrbetriq · DIN 02402882 Manufacturer: Astellas Pharma Canada Inc.; listing date 2015-05-28 Health Canada: Marketed since 2013-03-28 · brand MYRBETRIQ · ATC G04BD12 MIRABEGRON · form Tablet (extended-release) · route Oral · ingredients MIRABEGRON 50 MG · company Astellas pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.7300 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88771 · Verify on the e-Formulary ↗ (DIN 02402882)

Source record
DIN 02402882: Myrbetriq Raw flags: sec12=Y, sec3=Y Item: 860000075; group id 876; item number 2116; lccId 00254; manufacturer id ASE Source form: ER Tab; strength: 50mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $1.4600; ministry $0.7300 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02402882 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88771
Interchangeable products
Apo-Mirabegron · DIN 02564971 · $0.7300 Auro-Mirabegron · DIN 02564955 · $0.7300
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02402882
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (86:00 SPASMOLYTICS) and how they are covered

Matched class: 86:00 SPASMOLYTICS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: OXTRIPHYLLINE Some products covered without a code (check the product listing): THEOPHYLLINE ANHYDROUS 86:00 SPASMOLYTICS

FESOTERODINE FUMARATE

· 6 products · Limited Use, codes 290 · strengths: 4mg, 8mg · Tab

OXTRIPHYLLINE

· 1 products · General benefit · strengths: 20mg/mL · O/L

THEOPHYLLINE ANHYDROUS

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 400mg, 600mg · SR Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 86:00 86:12:04 Antimuscarinics

PROPIVERINE HYDROCHLORIDE

· 1 products · Limited Use, codes 530 · strengths: 5mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 86:12:04
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: overactive bladder
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. DARIFENACIN · Limited Use, codes 290 INDICATIONS AND CLINICAL USE ENABLEX (darifenacin) is indicated for the treatment of overactive bladder. PM: https://pdf.hres.ca/dpd_pm/00049667.PDF; date not captured; DIN 02273217; fetched 2026-09-10 Product monograph PROPIVERINE HYDROCHLORIDE · Limited Use, codes 530 INDICATIONS AND CLINICAL USE Mictoryl/Mictoryl Pediatric (propiverine hydrochloride) is indicated for symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in patients with overactive bladder (OAB). PM: https://pdf.hres.ca/dpd_pm/00043480.PDF; date January 15, 2018; DIN 02460289; fetched 2026-09-10 Product monograph SOLIFENACIN SUCCINATE · Limited Use, codes 290 INDICATIONS AND CLINICAL USE VESICARE® (solifenacin succinate) is indicated for:  Treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urinary urgency and urinary frequency. PM: https://pdf.hres.ca/dpd_pm/00048963.PDF; date December 31, 2018; DIN 02277263; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE MYRBETRIQ (mirabegron) is indicated for the treatment of overactive bladder (OAB) with symptoms of urgency, urgency incontinence and urinary frequency. Geriatrics (≥ 65 years of age): Of 5648 patients who received MYRBETRIQ in the phase 2 and 3 studies, 2029 (35.9%) were 65 years of age or older, and 557 (9.9%) were 75 years of age or older. No overall differences in safety or effectiveness were observed between patients younger than 65 years of age and those 65 years of age or older in these studies. Pediatrics (< 18 years of age): The safety and efficacy of MYRBETRIQ in pediatric patients have not been established. https://pdf.hres.ca/dpd_pm/00035298.PDF PM date: June 02, 2016 Source product: MYRBETRIQ; DIN 02402874; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.